JP2024503685A5 - - Google Patents
Info
- Publication number
- JP2024503685A5 JP2024503685A5 JP2023542757A JP2023542757A JP2024503685A5 JP 2024503685 A5 JP2024503685 A5 JP 2024503685A5 JP 2023542757 A JP2023542757 A JP 2023542757A JP 2023542757 A JP2023542757 A JP 2023542757A JP 2024503685 A5 JP2024503685 A5 JP 2024503685A5
- Authority
- JP
- Japan
- Prior art keywords
- heterodimer
- polypeptides
- nucleic acid
- polypeptide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163136687P | 2021-01-13 | 2021-01-13 | |
| US63/136,687 | 2021-01-13 | ||
| US202163139331P | 2021-01-20 | 2021-01-20 | |
| US63/139,331 | 2021-01-20 | ||
| PCT/IL2022/050055 WO2022153307A1 (en) | 2021-01-13 | 2022-01-13 | Type i membrane proteins heterodimers and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503685A JP2024503685A (ja) | 2024-01-26 |
| JP2024503685A5 true JP2024503685A5 (enExample) | 2024-12-13 |
Family
ID=82447997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542757A Pending JP2024503685A (ja) | 2021-01-13 | 2022-01-13 | Ｉ型膜タンパク質ヘテロダイマー及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076346A1 (enExample) |
| EP (1) | EP4277923A4 (enExample) |
| JP (1) | JP2024503685A (enExample) |
| KR (1) | KR20230169933A (enExample) |
| AU (1) | AU2022208466A1 (enExample) |
| BR (1) | BR112023013898A2 (enExample) |
| CA (1) | CA3204707A1 (enExample) |
| IL (1) | IL304381A (enExample) |
| MX (1) | MX2023008351A (enExample) |
| WO (1) | WO2022153307A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| CN111454369A (zh) * | 2020-04-10 | 2020-07-28 | 润方(长春)生物科技有限公司 | 一种用于制备异二聚物蛋白质的方法 |
| US20250051410A1 (en) * | 2021-12-23 | 2025-02-13 | Kahr Medical Ltd. | Lilrb polypeptides and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO2014164519A1 (en) * | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| CN113831417B (zh) * | 2017-05-08 | 2024-10-01 | 上海津曼特生物科技有限公司 | 双特异性重组蛋白及其应用 |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| EP3908664A4 (en) * | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| EP3947460A4 (en) * | 2019-03-26 | 2023-05-10 | Forty Seven, Inc. | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER |
| TWI760751B (zh) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| CN110128550B (zh) * | 2019-05-30 | 2023-01-13 | 南京惟亚德生物医药有限公司 | 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用 |
| US20220267409A1 (en) * | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
-
2021
- 2021-01-13 US US18/272,154 patent/US20240076346A1/en active Pending
-
2022
- 2022-01-13 AU AU2022208466A patent/AU2022208466A1/en active Pending
- 2022-01-13 KR KR1020237027209A patent/KR20230169933A/ko active Pending
- 2022-01-13 WO PCT/IL2022/050055 patent/WO2022153307A1/en not_active Ceased
- 2022-01-13 EP EP22739265.1A patent/EP4277923A4/en active Pending
- 2022-01-13 MX MX2023008351A patent/MX2023008351A/es unknown
- 2022-01-13 BR BR112023013898A patent/BR112023013898A2/pt unknown
- 2022-01-13 CA CA3204707A patent/CA3204707A1/en active Pending
- 2022-01-13 JP JP2023542757A patent/JP2024503685A/ja active Pending
-
2023
- 2023-07-10 IL IL304381A patent/IL304381A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503685A5 (enExample) | ||
| EA202192103A1 (ru) | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) | |
| Gerecke et al. | The complete primary structure for a novel laminin chain, the laminin B1k chain | |
| JP2023538891A5 (enExample) | ||
| AU2018264321A1 (en) | Bispecific recombinant protein and use thereof | |
| JP2019519215A5 (enExample) | ||
| WO2024047558A3 (en) | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e | |
| JP2013541335A5 (enExample) | ||
| BRPI0507433B8 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
| JP2019520591A5 (enExample) | ||
| ATE387458T1 (de) | Fas-antigenbindender ligand | |
| WO2024020591A3 (en) | Antigen binding molecules targeting thymic stromal lymphopoietin (tslp) | |
| JP2024502479A5 (enExample) | ||
| JP2022164822A5 (enExample) | ||
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
| de Moura et al. | Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22 | |
| BR112022007619A2 (pt) | Molécula de ligação específica, molécula de fusão de molécula de ligação específica anti-cd3, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou geneticamente modificada, composição farmacêutica, método para tratar um sujeito humano com câncer ou tumor e método para produzir uma molécula de ligação específica | |
| WO2021226289A3 (en) | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins | |
| CN106117367B (zh) | 一种her-3特异性嵌合抗原受体及其应用 | |
| JP2020521000A5 (enExample) | ||
| WO2021263167A3 (en) | Il-10 muteins and fusion proteins thereof | |
| CN103910796A (zh) | 一种全人源抗狂犬病毒的中和抗体 | |
| CN117886919A (zh) | 识别HLA-A2限制性乙肝病毒HBs346-354表位的TCR及其用途 | |
| WO2023150724A3 (en) | Antigen binding proteins that bind b7-h3 | |
| MX2024003804A (es) | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih. |